Yuan Xue, PhD

Yuan Xue, PhD, is Vice President, Head of Regulatory Affairs at Aktis Oncology. He brings broad experience in clinical drug development and translational research, with a career spanning both industry and academia. Yuan has led global regulatory strategies and operations for numerous programs, successfully overseeing the clearance of dozens of INDs and guiding multiple first-in-class compounds through development to global approvals. Prior to joining Aktis, he served as Senior Vice President at Accutar Biotech, where he was responsible for regulatory strategy and operations across a portfolio of oncology assets. Earlier in his career, Yuan was at the Global Regulatory Affairs-Oncology team at Merck. There, he led global regulatory strategy for Phase 1–3 development of the Keytruda® renal cell carcinoma program, and played a key role in achieving global approvals for Welireg® (belzutifan). At Bayer, he led both early- and late-stage oncology programs, including Vitrakvi® (larotrectinib), Xofigo® (radium-223), and Nexavar® (sorafenib). Yuan earned his PhD in Medicine from the Karolinska Institute and completed his postdoctoral training in the Langer Lab at the Massachusetts Institute of Technology. Outside of work, he enjoys visiting museums and exploring cities and nature with his family.